Guidance for Providers Offering Misoprostol-Alone for Abortion Amidst COVID-19 (CEDES, Gynuity)
Guidance for Providers Offering Misoprostol-Alone for Abortion Amidst COVID-19
Authors: CEDES and Gynuity
Collaborators: ASAP, CLACAI, Women Help Women and REDAAS
Year: July 2020
This resource offers evidence-based guidance on abortion with misoprostol alone while limiting clinic visits and required tests to ensure the continuity of care. It can help providers make evidencebased adjustments in clinical practice to enable safe access to high quality care while limiting unnecessary visits to medical facilities and possibly reducing costs to people seeking abortion and to the health system. The guidance was developed in accordance with the World Health Organization’s and the International Federation of Gynecology and Obstetrics’ calls to maintain essential reproductive health services during the COVID-19 emergency1,2 and presents options for simplifying care after the crisis has passed.